Skip to content
Screener

Kura Oncology KURA Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$20.8MMiss by $30.7M
EPS-$0.85Miss by $0.28
Revenue estimate$51.4M
EPS estimate-$0.57

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$23.8M
EPS estimate-$0.84

Financials

Q3 2025

Income statement

See full
Revenue$20.8M+54.0%
Operating income-$80.0M-33.6%
Net income-$74.1M-36.2%
EPS (diluted)-$0.85-34.9%

Balance sheet

See full
Cash & equivalents$95.3M+92.6%
Total debt$19.5M+17.1%
Total equity$242.5M-42.8%
Total assets$649.4M+35.6%

Cash flow

See full
Operating cash flow-$80.6M-85.6%
CapEx$2.6M—
Free cash flow-$83.2M-91.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$768.16M-54.6%
Enterprise value$692.33M-58.3%
P/S12.1×-29.8×

Profitability

See full
Operating margin-377%-82.9pp
Net margin-340.9%-79.2pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-65.1%+44.6pp
Debt / equity0.1×0.0×
Current ratio5.1×-6.4×

FAQ

When did Kura Oncology report Q3 2025 earnings?
Kura Oncology (KURA) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Kura Oncology's Q3 2025 revenue and EPS?
Kura Oncology reported revenue of $20.8M and eps of $-0.85 for Q3 2025.
Did Kura Oncology beat estimates in Q3 2025?
Revenue missed the consensus estimate of $51.4M by $30.7M. EPS missed the consensus estimate of $-0.57 by $0.28.
How did Kura Oncology's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 34.9% from $-0.63.
Where can I find Kura Oncology's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-263491) and the 10-Q periodic report (0001193125-25-263589) directly on SEC EDGAR. The filing index links above go to sec.gov.